Within the last few years, we have witnessed a significant increase in cataract and presbyopic patients' expectations and
demands regarding refractive outcomes and spectacle-free options.
Features of the Diffractiva Diff-aA
These expectations have been in part fuelled by significant breakthroughs in multifocal intraocular lens (MIOL) technology
and results. Still, the refractive IOL market is constantly evolving to optimize refractive results with minimum side-effects
and to offer patients optimal uncorrected visual acuity at distance, intermediate and near distances.
Our initial reasons for performing this study were to evaluate the visual performance of the new onepiece hydrophilic acrylic
single piece diffractive MIOL, the Diffractiva Diff-aA, that has been commercially available from HumanOptics (Erlangen, Germany)
since September 2010 (Figure 1), as well as evaluating the new lens injector devoted to the lens and the level of patient
satisfaction achieved. Independently of this study we have already achieved results with several other diffractive MIOLs and
so in this recent investigation we could compare the outcomes with a focus on the intermediate visual acuity gains (depth
of focus) and reduction in night vision problems.
Figure 1: The Diffractiva-aA.
The Diffractiva Diff-aA MIOL is currently under clinical evaluation in a multicentre study in which seven participating University
or Private Clinics in France, Austria, UK and Libanon are taking part. A total enrollment of 45 patients (90 eyes) with bilateral
cataract and eligible for MIOL implantation has been targeted. Ophthalmic examinations including refraction, monocular and
binocular visual acuity for far, intermediate (1 m) and near (40 cm) distances have been scheduled at 1-month, 3-months and
6-months postoperatively. Evaluation of contrast sensitivity and defocus curve has been scheduled at 6 months postoperatively,
patient satisfaction (quality-of-life questionnaire) at 3 and 6-months postoperatively.